Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
As antimicrobial resistance, also known as AMR continues to climb — the WHO now calls it a top 10 global health threat — antimicrobial peptides (AMPs) are emerging as one of the most promising alternatives to conventional antibiotics.
Why AMPs Matter Now
Unlike traditional small-molecule antibiotics that target specific enzymes or pathways, AMPs disrupt bacterial membranes through physical mechanisms — making resistance development dramatically slower. After decades of academic research, several AMPs have now reached late-stage clinical trials, and the first wave of commercial products is reaching the market.
Clinical Pipeline Highlights
Several candidates are worth watching. Iseganan, also known as IB-367 is in Phase 3 for oral mucositis. Pexiganan, also known as MSI-78 targets diabetic foot infections. PL-5, a synthetic alpha-helical AMP is in Phase 3 for skin and soft tissue infections. On the agricultural side, Nisin-based formulations have been used as food preservatives for years, and plant-expressed AMPs are entering field trials for crop protection.
Delivery and Stability Challenges
The historical barriers to AMP development — protease susceptibility, systemic toxicity, and manufacturing cost — are being systematically addressed. PEGylation, lipidation, cyclization, and D-amino acid substitution improve half-life. Lipid nanoparticle and polymer-based delivery systems protect peptides in circulation. And advances in recombinant expression — yeast, E. coli, plant-based — are bringing production costs down from thousands to hundreds of dollars per gram.
The Investment Landscape
Venture funding for AMP-focused biotechs has risen steadily, with over two billion dollars invested since 2020. Key players include Polyphor — now Spexis —, Adenium Biotech, and academic spinouts from MIT, UCSF, and the University of Queensland. The market for peptide antibiotics alone is projected at $5–8 billion by 2032.
[Natural sign-off — one sentence summary of why this matters.]
